Тюрина E. В., Валиев, Т. Т., Кумирова, Э. В., Романцова, О. М., & Варфоломеева, С. Р. (2024). Атипичные тератоид-рабдоидные опухоли центральной нервной системы у детей. Обзор литературы. VOPROSY ONKOLOGII, 70(4), 622–632. https://doi.org/10.37469/0507-3758-2024-70-4-622-632

摘要

Атипичные тератоид-рабдоидные опухоли (АТРО) — высокоагрессивные злокачественные новообразования центральной нервной системы (ЦНС), преимущественно диагностируемые у детей раннего возраста. Несмотря на комплексные подходы в терапии, включающие хирургическое, химиотерапевтическое, лучевое лечение, применение таргетных препаратов и иммунотерапии, результаты остаются крайне неблагоприятными. Современные эпидемиологические и молекулярно-биологические исследования, направленные на изучение этиологии возникновения опухолей, молекулярных характеристик злокачественных новообразований, определение возможности применения таргетных препаратов, позволят продвинуться в понимании структуры процесса и улучшить выживаемость пациентов.

https://doi.org/10.37469/0507-3758-2024-70-4-622-632

##article.numberofdownloads## 105

##article.numberofviews## 192

pdf (Русский)

参考

Fossey M., Li H., Afzal S., et al. Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. J Neurooncol. 2017; 132(1): 155-62.-DOI: https://doi.org/10.1007/s11060-016-2353-0.

Judkins A.R., Eberhart C.G., Wesseling P. Atypical teratoid/rhabdoid tumor. In: World Health Organization classification of tumors: pathology and genetics of central nervous system. Lyon: IARC Press. 2007: 147-149.

Nesvick C.L., Lafay-Cousin L., Raghunathan A., et al. Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. J Neurooncol. 2020; 150(1): 47-56.-DOI: https://doi.org/10.1007/s11060-020-03639-w.

Fruwald M., Hasselblatt M., Nemes K., et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro Oncol. 2019; 22(7): 1006-17.-DOI: https://doi.org/10.1093/neuonc/noz244.

Nemes K. Infants and newborns with atypical teratoid rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors (eMRT) in the EU-RHAB registry: a unique and challenging population. Cancers. 2022; 14(9): 2185.-DOI: https://doi.org/10.3390/cancers14092185.

Upadhyaya S.A., Robinson G.W., Thomaset A.O. Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective st. jude multi-institutional trials. Clin Cancer Res. 2021; 27(10): 2879-2889.-DOI: https://doi.org/10.1158/1078-0432.CCR-20-4731.

McNeill K.A. Epidemiology of brain tumors. Neurol Clin. 2016; 34(4): 981-98.-DOI: https://doi.org/10.1016/j.ncl.2016.06.014.

Ostrom Q., Patil N., Cioffi G., et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(Supplement_1): iv1–96.-DOI: https://doi.org/10.1093/neuonc/noaa200.

Louis D., Perry A., Reifeberger G., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803-20.-DOI: https://doi.org/10.1007/s00401-016-1545-1.

Cosnarovici M.M., Cosnarovici R.V., Piciu D. Updates of the 2016 World Health Organization Classification of Pediatric Tumors of the Central Nervous System - a systematic review. Med Pharm Rep. 2021; 94(3): 282-8.-DOI: https://doi.org/10.15386/mpr-1811.

Louis D., Perry A., Wesseling P., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231-51.-DOI: https://doi.org/10.1093/neuonc/noab106.

Rushing E.J. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition. MEMO. 2021; 14(2): 188-91.-DOI: https://doi.org/10.1007/s12254-021-00680-x.

Ольхова Л.В. Прогностические факторы и влияние высокодозной полихимиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток на результаты лечения атипичных тератоид-рабдоидных опухолей центральной нервной системы у детей. Диссертация на соискание ученой степени кандидата медицинских наук. Федеральное государственное бюджетное учреждение «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства». 2022; 169. URL: https://www.1spbgmu.ru/images/home/universitet/Struktura/Soveti_i_Komissii/Dissertacii/%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0/%D0%9A%D0%B0%D0%BD%D0%B4.%D0%B4%D0%B8%D1%81%D1%81%D0%B5%D1%80%D1%82%D0%B0%D1%86%D0%B8%D1%8F_%D0%90%D0%A2%D0%A0%D0%9E_%D0%A6%D0%9D%D0%A1_%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0_%D0%9B.pdf. [Olkhova L.V. Prognostic factors and the influence of high-dosed polychemotherapy with autologous stem cell transplantation on treatment results of pediatric atypical teratoid/rhabdoid tumors of central nervous system. Dissertation for the degree of Candidate of Medical Sciences. FSBI «Russian Research Institute of Hematology and Transfusiology of the Federal Medical-Biological Agency». 2022; 169. 2022; 169. URL: https://www.1spbgmu.ru/images/home/universitet/Struktura/Soveti_i_Komissii/Dissertacii/%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0/%D0%9A%D0%B0%D0%BD%D0%B4.%D0%B4%D0%B8%D1%81%D1%81%D0%B5%D1%80%D1%82%D0%B0%D1%86%D0%B8%D1%8F_%D0%90%D0%A2%D0%A0%D0%9E_%D0%A6%D0%9D%D0%A1_%D0%9E%D0%BB%D1%8C%D1%85%D0%BE%D0%B2%D0%B0_%D0%9B.pdf (in Rus)].

Torchia J., Golbourn B., Feng S., et al. Integrated (epi)-genomic analyses iden- tify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell. 2016; 30: 891-908.-DOI: https://doi.org/10.1016/j. ccell.2016.11.003.

Frühwald M.C., Graf N. European Rhabdoid Registry. A multinational registry for rhabdoid tumors of any anatomical site V2.2010. 2010; 398. URL: https://www.orpha.net/pdfs/data/prj/DE/Reg77865GB.pdf.

Zimmerman M.A., Turner Ch., Chordas Ch., et al. Chemo/radiation therapy for CNS AT/RT. Version 1.7/6-9-2006.

Park M., Han J.W., Hahn S.M., et al. Atypical teratoid/rhabdoid tumor of the central nervous system in children under the age of 3 years. Cancer Res Treat. 2021; 53(2): 378-88.-DOI: https://doi.org/10.4143/crt.2020.756.

Zhang C., Li H. Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. Pediatr Investig. 2022; 6(2): 111-22.-DOI: https://doi.org/10.1002/ped4.12325.

Tran H.M., Wu K.S., Sung S.Y., et al. Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor borte- zomib in myc-atypical teratoid/rhabdoid tumors. Cancers. 2020; 12.-DOI: https://doi.org/10.3390/cancers12030752.

Kim S.H. Yesterdays, todays, and tomorrows – Korean Society for Pediatric Neuro-Oncology. Brain Tumor Res Treat. 2023; 11(3): 177-182.-DOI: https://doi.org/10.14791/btrt2023.0018.

Slavc I., Chocholous M., Leiss U., et al. Atypical teratoid rhabdoid tumor: improved long‐term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992–2012. Cancer Med. 2013; 3(1): 91-100.-DOI: https://doi.org/10.1002/cam4.161.

Ольхова Л.В., Кушель Ю.В., Кадыров Ш.У., et al. Влияние радикальности оперативного вмешательства на результаты лечения атипичной тератоидно-рабдоидной опухоли центральной нервной системы у детей. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2021; 85(2): 17‑25. [Olkhova L.V, Kushel Yu.V., Kadyrov Sh.U. et al. The influence of radical surgery on treatment results of pediatric atypical teratoid/rhabdoid tumors of central nervous system. Burdenko's Journal of Neurosurgery. 2021; 85(2): 17-25. (in Rus)].

Kerl K., Ries D., Unland R., et al. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells. BMC Cancer. 2013; 13: 286.-DOI: https://doi.org/10.1186/1471-2407-13-286.

Zhang C., Li H. Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors. Pediatr Investig. 2022; 6: 111-122.-DOI: https://doi.org/10.1002/ped4.12325.

Tran H.M., Wu K.S., Sung S.Y. et al. Upregulation of protein synthesis and proteasome degradation confers sensitivity to proteasome inhibitor borte- zomib in myc-atypical teratoid/rhabdoid tumors. Cancers. 2020;12. DOI: https://doi.org/10.3390/cancers12030752.

Alimova I. ATRT-01. PARP Inhibition as a therapeutic target in ATRO. Neuro Oncol. 2023; 25(Suppl 1): i1.-DOI: https://doi.org/10.1093/neuonc/noad073.001.

Zhibin Li. Atypical teratoid/rhabdoid tumor with CDK6 amplification in a child: a case report and literature review. Front Pediatr. 2023; 11: 1237572.-DOI: https://doi.org/10.3389/fped.2023.1237572.

Forrest S.J. Genomic and immunologic characterization of INI1-deficien pediatric cancers. Clin Cancer Res. 2020; 26 (12): 288202890.-DOI: https://doi.org/10.1158/1078-0432.CCR-19-3089.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.